Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion

Dermatology Online Journal

Volumn 13, Issue 3, 2007, Pages

  Rosen, Ted ^a   Doherty, Christy ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; PENTOXIFYLLINE; PREDNISONE; STEROID; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LONG TERM CARE; MONOTHERAPY; PHYSICAL EXAMINATION; SARCOIDOSIS; SKIN BIOPSY; THORAX RADIOGRAPHY; TREATMENT FAILURE; UPPER RESPIRATORY TRACT; BIOPSY; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NOSE DISEASE; PATHOLOGY; SKIN DISEASE; TIME;

ANTIBODIES, MONOCLONAL; BIOPSY; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NOSE DISEASES; SARCOIDOSIS; SKIN DISEASES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547233169     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007;56(1):69-83.
2. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18(1):70-74.
3. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003;2(4):413-414.
4. Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factoralpha therapy. J Am Acad Dermatol 2003;48(2):290-293.
5. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124(5):2028-2031.
6. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004;150(1):146-149.
7. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005;141(7):910-911.
8. Baughman RP, Iannuzzi M. Tumor necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 2003;17(6):425-431.
9. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharm Exp Ther 2002;301(2):418-426.
10. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7(3):251-259.
11. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127(3):1064-1071.
12. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: Different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36(3):159-67.